Sandoz to Pay $478.5 Million to Settle Price-Fixing Allegations in Long-Running Battle With States

Sandoz, the Novartis generics business, has agreed to pay $478.5 million to settle allegations that the company engaged in a conspiracy to artificially inflate and manipulate prices, STAT reported on August 3. The settlement ends a long-running legal battle with multiple US state attorneys general.

What the Case Was About

The case involved allegations that Sandoz and other generic drug manufacturers coordinated price increases on a number of off-patent drugs over several years. The alleged scheme involved sharing competitive information and aligning pricing strategies through industry meetings and direct communications. The conduct predated Sandoz's spin-off from Novartis in 2023.

"Sandoz agreed to pay $478.5 million to settle allegations that the company engaged in a conspiracy to artificially inflate and manipulate prices," STAT wrote.

Why It Matters

The settlement is one of the largest in a series of generics price-fixing cases that have proceeded through state and federal courts over the past several years. Several other manufacturers have settled similar cases for comparable amounts. The total penalties across the industry now exceed several billion dollars, and additional cases remain pending.

What's Next

Sandoz has not admitted wrongdoing as part of the settlement, which is typical for these cases. The company said the settlement removes uncertainty and allows it to focus on its business. State attorneys general said the settlement sends a clear message that price-fixing in the generics market will not be tolerated.